Does Network Health Cover Propecia?

How Network Health Handles Hair Loss Medications

Most Network Health insurance plans treat hair loss as a cosmetic concern and exclude brand-name Propecia from standard formulary coverage. This mirrors a pattern seen across commercial insurers in Wisconsin, where Network Health primarily operates. Generic finasteride 1 mg has a slightly better chance of coverage, but plan-specific exclusions apply.

Network Health offers multiple plan types, including Medicare Advantage, Medicaid (BadgerCare Plus), and commercial marketplace options. Each product line maintains its own formulary. Medicare Advantage plans follow CMS guidelines, which generally do not mandate coverage for cosmetic indications [1]. Commercial and marketplace plans set their own exclusion lists, and hair loss medications appear on most of them.

The distinction between brand Propecia and generic finasteride matters here. Propecia carries an average retail price of $70 to $120 for a 30-day supply, while generic finasteride 1 mg costs $8 to $30 depending on pharmacy [2]. Even when a plan excludes both from formulary coverage, the generic version remains affordable enough that many patients pay cash without filing a claim. Network Health members should check their Summary of Benefits and Coverage document or call the pharmacy benefits number on their member ID card to confirm their specific plan's formulary status.

A 2022 analysis published in the Journal of the American Academy of Dermatology found that only 28% of commercial insurance plans covered any oral finasteride formulation for alopecia, compared with 91% coverage for the same drug at the 5 mg BPH dose [3]. This gap reflects how payers categorize indications rather than the drug itself.

Why Insurers Classify Propecia as Cosmetic

The short answer: the FDA approval indication. Propecia received FDA approval in December 1997 specifically for treatment of male pattern hair loss (androgenetic alopecia) in men [4]. Insurers routinely classify hair loss treatments as cosmetic because alopecia does not meet their internal definitions of a medically necessary condition requiring pharmacotherapy.

This classification persists despite growing evidence that androgenetic alopecia carries measurable psychological burden. A 2019 study in the British Journal of Dermatology (N=729) found that men with pattern hair loss scored significantly higher on the Dermatology Life Quality Index, with 29% reporting moderate-to-severe psychological impact [5]. The Endocrine Society's 2017 clinical practice guidelines acknowledge the androgen-mediated mechanism of AGA but stop short of recommending insurance mandate language for 5-alpha reductase inhibitors in this context [6].

Network Health, like most regional HMO and PPO carriers, follows benefit design standards set by actuarial models that weigh condition severity against treatment cost. Hair loss falls below the threshold that triggers mandatory formulary inclusion. This is not a medical judgment about finasteride's efficacy. It is a benefits administration decision.

The Generic Finasteride Workaround

Generic finasteride 1 mg is the practical path forward for most Network Health members. Patent exclusivity for Propecia expired in 2013, and multiple manufacturers now produce FDA-approved generic versions at a fraction of the brand cost.

Here is what the cost picture looks like without insurance:

At major chain pharmacies (CVS, Walgreens, Walmart), a 30-day supply of generic finasteride 1 mg ranges from $15 to $30 at retail. With a GoodRx or RxSaver coupon, prices drop to $8 to $15 in most Wisconsin ZIP codes. Mail-order pharmacies and telehealth platforms like HealthRX often offer 90-day supplies for $24 to $45, which brings the per-month cost below $15.

For comparison, the 5 mg finasteride tablet (generic Proscar, approved for benign prostatic hyperplasia) is more commonly covered by insurance. Some physicians prescribe finasteride 5 mg off-label for hair loss and instruct patients to quarter the tablet, though this approach lacks standardized dosing validation and the FDA has not approved this use. A 2020 pharmacokinetic analysis in Clinical Pharmacology & Therapeutics showed that quartered 5 mg tablets produced serum finasteride concentrations approximately 15 to 20% higher than 1 mg tablets, with greater dose variability between quarters [7]. Patients considering this route should discuss it with their prescriber.

How to Check Your Specific Network Health Plan

The fastest way to determine coverage is a three-step process. First, locate your plan's formulary on the Network Health member portal or request it by calling the number on your member card. Second, search for "finasteride" rather than "Propecia," since generic names are how formularies are indexed. Third, note the tier assignment and any coverage restrictions (prior authorization, step therapy, quantity limits).

If finasteride does not appear on your formulary at all, your options include:

Filing a formulary exception request through your prescribing physician. This requires a letter of medical necessity explaining why finasteride is appropriate for your condition. Success rates for cosmetic-indication exceptions are low (estimated at 10 to 15% based on industry data), but documented psychological comorbidity strengthens the case [8].

Using an external pharmacy discount program. GoodRx, SingleCare, and RxSaver all offer coupons that work at Network Health-contracted pharmacies. These discounts apply at the point of sale and do not require insurer approval.

Switching to a telehealth prescription service. Platforms that include the medication cost in a monthly subscription fee bypass insurance entirely and often match or beat retail pharmacy pricing.

Finasteride Efficacy: What the Evidence Shows

Finasteride 1 mg works by inhibiting the Type II 5-alpha reductase enzyme, which converts testosterone to dihydrotestosterone (DHT). DHT is the primary androgen responsible for miniaturization of hair follicles in genetically susceptible men. By reducing scalp DHT concentrations by approximately 64%, finasteride slows follicular miniaturization and, in many patients, allows partial regrowth [9].

The key trials supporting FDA approval enrolled 1,879 men aged 18 to 41 with mild-to-moderate vertex hair loss. At 12 months, 48% of men taking finasteride 1 mg daily showed visible hair regrowth on investigator assessment, compared with 7% on placebo. At 24 months, 83% of finasteride-treated men maintained or increased hair counts versus baseline, while 72% of placebo-treated men continued to lose hair [10].

Long-term data from a 5-year extension study (N=1,215) published in the European Journal of Dermatology confirmed durability: men who remained on finasteride maintained hair count increases averaging 277 hairs in a 1-inch diameter target area, while the placebo group lost an average of 139 hairs in the same area [11]. Discontinuation leads to reversal of benefits within 6 to 12 months as DHT levels normalize.

These numbers matter for the insurance conversation because they demonstrate that finasteride is not a marginal treatment. It has a strong evidence base with consistent results across multiple randomized controlled trials.

Side Effects and Safety Considerations

The most commonly cited concerns involve sexual side effects. In the original key trials, 3.8% of finasteride-treated men reported decreased libido, 1.3% reported erectile dysfunction, and 1.2% reported decreased ejaculate volume, compared with 2.1%, 0.7%, and 0.7% in the placebo group respectively [10]. The absolute risk increase is small, and the majority of affected men reported resolution after discontinuation.

Post-finasteride syndrome (PFS), a proposed constellation of persistent sexual, neurological, and psychological symptoms after finasteride discontinuation, has been described in case reports and patient surveys. The Endocrine Society and the American Urological Association have not recognized PFS as an established diagnosis. A 2023 systematic review in Andrology (32 studies, N=29,834) found that the incidence of persistent sexual adverse events attributable to finasteride ranged from 0.9% to 1.5%, though the authors noted significant heterogeneity in study design and outcome measurement [12].

The FDA added warnings about depression and suicidal ideation to the finasteride label in 2012 based on post-marketing surveillance reports [4]. Patients starting finasteride should discuss baseline mood and sexual function with their provider and report any changes promptly. These are real but uncommon risks that warrant informed consent, not avoidance of an effective treatment.

Comparing Finasteride With Other Hair Loss Treatments

Minoxidil (Rogaine) is the other FDA-approved treatment for androgenetic alopecia and is available over the counter. A 48-week randomized trial (N=393) comparing finasteride 1 mg daily with topical minoxidil 5% twice daily found that finasteride produced superior hair count increases: +16.5 hairs per cm² versus +11.9 hairs per cm² in the vertex scalp [13]. Combination therapy (finasteride plus minoxidil) produced the best outcomes in a 2015 Indian Journal of Dermatology trial (N=100), with 94% of combination-treated men showing improvement at 12 months versus 80% for finasteride alone and 59% for minoxidil alone [14].

Insurance coverage for minoxidil is a non-issue since it is OTC. A 3-month supply of generic topical minoxidil 5% costs $15 to $25 at most retailers. Oral minoxidil at low doses (2.5 to 5 mg daily) is prescribed off-label for hair loss and may appear on formularies since it carries a primary indication for hypertension, though prescribers must document the intended use.

Dutasteride (Avodart) inhibits both Type I and Type II 5-alpha reductase and reduces serum DHT by over 90%. It is FDA-approved for BPH only, but off-label use for hair loss is common in dermatology practice. A phase III trial conducted in South Korea and published in the Journal of the American Academy of Dermatology (N=917) showed that dutasteride 0.5 mg was superior to finasteride 1 mg in hair count improvement at 24 weeks (+12.2 vs. +4.7 hairs per cm²) [15]. Network Health plans are more likely to cover dutasteride for a BPH diagnosis than for alopecia.

What Network Health Medicare Advantage Members Should Know

Medicare Part D formularies follow CMS coverage determination guidelines, which explicitly exclude drugs "used for cosmetic purposes or hair growth" from mandatory coverage [1]. This means Network Health Medicare Advantage plans will not cover finasteride 1 mg or Propecia for hair loss under the Part D pharmacy benefit.

There is one exception pathway. If a Medicare Advantage member has a concurrent diagnosis of benign prostatic hyperplasia, finasteride 5 mg (Proscar) is a covered Part D drug. The prescribing physician's diagnosis code on the prescription determines whether the claim processes. A hair loss diagnosis code (L64.0, androgenetic alopecia) will be rejected. A BPH diagnosis code (N40.0 or N40.1) will typically be covered at the Tier 1 or Tier 2 copay level.

Medicare members should never submit false diagnosis information to obtain coverage. If both conditions are genuinely present, the prescriber can legitimately use the BPH indication. The 5 mg dose will need to be adjusted per the prescriber's instructions if the intent is also to address hair loss, and the patient should understand this represents off-label dosing for the alopecia component.

How HealthRX Can Help With Finasteride Access

For patients whose Network Health plan does not cover finasteride for hair loss, telehealth platforms offer a streamlined alternative. HealthRX connects patients with licensed providers who evaluate candidacy for finasteride through a structured online consultation. If appropriate, a prescription is sent to a partnered pharmacy or fulfilled through direct-to-patient shipping.

This model eliminates the insurance authorization process entirely. Pricing is transparent and typically competitive with or lower than retail pharmacy cash prices. Patients receive ongoing provider oversight, including check-ins to monitor for side effects and assess treatment response. Lab work, including baseline PSA for men over 40, can be ordered through the platform.

The clinical workflow matters. Finasteride is a prescription medication that requires medical evaluation. Responsible telehealth prescribing includes screening for contraindications (finasteride is contraindicated in women who are or may become pregnant due to teratogenicity risk), discussing realistic outcome timelines (visible results typically require 6 to 12 months of continuous use), and establishing follow-up protocols [4].

Wisconsin Prescription Assistance Programs

Wisconsin residents enrolled in Network Health who face cost barriers have several state-level resources. The Wisconsin Department of Health Services maintains a prescription assistance information page that lists patient assistance programs operated by pharmaceutical manufacturers [16]. While Merck (the original Propecia manufacturer) discontinued its branded patient assistance program after patent expiration, several generic manufacturers offer discount cards.

NeedyMeds (needymeds.org) and RxAssist (rxassist.org) maintain searchable databases of patient assistance programs, discount cards, and state-funded prescription aid. Wisconsin does not operate a state pharmaceutical assistance program (SPAP) for non-elderly adults, so these nonprofit databases are the primary resource for patients under 65.

For Network Health BadgerCare Plus members, generic finasteride may be covered if the prescriber can document medical necessity beyond cosmetic indication. BadgerCare Plus formulary decisions are made by the Wisconsin Department of Health Services Pharmacy Benefits Management unit. Preferred drug list updates occur quarterly, and members or providers can request a Prior Authorization through the standard DHS process [17].

Patients filling finasteride prescriptions out of pocket should compare prices across at least three pharmacies. A 2021 JAMA Internal Medicine study found that cash prices for the same generic drug varied by as much as 600% between pharmacies within the same ZIP code [18]. Price-comparison tools reduce this variability significantly.